Fixed-dose vs free-dose combinations for the management of hypertension—An analysis of 81 958 patients

Journal of Clinical Hypertension

Volumn 20, Issue 4, 2018, Pages 705-715

  Bramlage, Peter ^a   Schmidt, Stefanie ^b   Sims, Helen ^a  

^a INSTITUTE FOR PHARMACOLOGY AND PREVENTIVE MEDICINE   (Germany)

^b Sandoz Biopharmaceuticals   (Germany)

Author keywords

adherence; angiotensin receptor blocker; angiotensin converting enzyme inhibitor; calcium antagonist; fixed dose combination; hypertension

Indexed keywords

AMLODIPINE PLUS CANDESARTAN; AMLODIPINE PLUS RAMIPRIL; ANTIHYPERTENSIVE AGENT; UNCLASSIFIED DRUG; AMLODIPINE; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; RAMIPRIL; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG FORMULATION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PILL; PRESCRIPTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; AGE; COMPARATIVE STUDY; DRUG COMBINATION; ECONOMICS; MIDDLE AGED; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; COMORBIDITY; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RAMIPRIL; TETRAZOLES;

EID: 85045522090     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.13240     Document Type: Article

References (32)

1. NCD-RisC. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37-55.
2. Hostalek U, Czarnecka D, Koch EMW. Treatment of hypertensive patients with a fixed-dose combination of bisoprolol and amlodipine: results of a cohort study with more than 10,000 patients. Cardiol Ther. 2015;4:179-190.
3. Laurent S, Parati G, Chazova I, et al. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. J Hypertens. 2015;33:653-661; discussion 662.
4. Takase B, Nagata M. Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study. Anadolu Kardiyol Derg. 2014;14:685-691.
5. Rakugi H, Tsuchihashi T, Shimada K, et al. Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. Clin Exp Hypertens. 2015;37:260-266.
6. Chrysant SG. Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. Expert Rev Cardiovasc Ther. 2013;11:1115-1124.
7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
8. Gupta P, Patel P, Štrauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69:1113-1120.
9. Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100.
10. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407.
11. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10:3-12.
12. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280-1288.
13. Davis JW, Chung R, Juarez DT. Prevalence of comorbid conditions with aging among patients with diabetes and cardiovascular disease. Hawaii Med J. 2011;70:209-213.
14. Kelly-Hayes M. Influence of age and health behaviors on stroke risk: lessons from longitudinal studies. J Am Geriatr Soc. 2010;58:S325-S328.
15. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322.
16. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254.
17. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
18. Adedeji AR, Tumbo J, Govender I. Adherence of doctors to a clinical guideline for hypertension in Bojanala district, North-West Province, South Africa. Afr J Prim Health Care Fam Med. 2015;7:1–6.
19. Helmert U, Mielck A, Classen E. Social inequities in cardiovascular disease risk factors in East and West Germany. Soc Sci Med. 1992;35:1283-1292.
20. Luschen G, Niemann S, Apelt P. The integration of two health systems: social stratification, work and health in East and West Germany. Soc Sci Med. 1997;44:883-899.
21. Weber F, Anlauf M. Treatment resistant hypertension – investigation and conservative management. Dtsch Arztebl Int. 2014;111:425-431.
22. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766-774.
23. Xie L, Frech-Tamas F, Marrett E, Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014;30:2415-2422.
24. Czarnecka D, Koch EM, Gottwald-Hostalek U. Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. Curr Med Res Opin. 2015;31:875-881.
25. Tung YC, Huang YC, Wu LS, Chang CJ, Chu PH. Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment. J Clin Hypertens (Greenwich). 2017;19:983-989.
26. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ. 2012;15:897-905.
27. Hess G, Hill J, Lau H, Dastani H, Chaudhari P. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P T. 2008;33:652-666.
28. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26:2065-2076.
29. Hong SH, Wang J, Tang J. Dynamic view on affordability of fixed-dose combination antihypertensive drug therapy. Am J Hypertens. 2013;26:879-887.
30. Hilleman DE. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management. J Manag Care Pharm. 2014;20:93-100.
31. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898-909.
32. Tung Y-C, Lin Y-S, Wu L-S, Chang C-J, Chu P-H. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. J Clin Hypertens (Greenwich). 2015;17:51-58.